Journal: Annual review of immunology
This review frames cancer as a disease of the human “metaorganism,” emphasizing that host cells and the microbiome jointly shape cancer risk, progression, and treatment response.
Key points:
-
• Microbiome–cancer biology: Commensal microorganisms, mainly at epithelial barriers, influence:
- • Genome stability and tissue organization
- • Chronic inflammation and immune tone
- • Tumor initiation, promotion, and metastasis
These effects can be pro- or antitumor depending on context and microbial composition.
-
• Impact on immunotherapy:
- • Specific microbiome features are associated with response or resistance to immune checkpoint inhibitors.
- • Machine learning models using microbiome data show moderate ability to predict clinical response and immune-related adverse events, suggesting potential for biomarker development but not yet clinical-grade performance.
-
• Fecal microbiota transplantation (FMT) in cancer care:
- • Single-arm and randomized studies demonstrate that FMT from immunotherapy responders or healthy donors, combined with PD-1 blockade, can:
- • Convert some PD-1–refractory patients into responders
- • Enhance outcomes as a first-line strategy in selected settings
- • These trials support a causal role of the microbiome in modulating immunotherapy efficacy.
- • Single-arm and randomized studies demonstrate that FMT from immunotherapy responders or healthy donors, combined with PD-1 blockade, can:
-
• Clinical opportunities and challenges:
- • Opportunities: Microbiome-based biomarkers, microbiome modulation (diet, probiotics, FMT, defined consortia) to improve efficacy and reduce toxicity of immunotherapy.
- • Challenges: Interindividual variability, lack of standardization in microbiome profiling and FMT protocols, safety concerns, regulatory issues, and the need for larger, controlled trials.
Overall, the article positions microbiome manipulation as a promising adjunct to immunotherapy but emphasizes that translation into routine oncology practice requires rigorous validation and standardized approaches.